- Prev close
- $186.43
- Day range
- $181.20 – $187.33
- From 52-wk high
- -12.4%
AstraZeneca’s +7.0% move lines up with a solid Q3 beat and management commentary on oncology and rare disease momentum, so the advance looks fundamentals-backed rather than market-driven.
AZN
ASTRAZENECA PLC
As of Nov 1, 2026
78/100
Looks healthyHealth ScorePrimary driver
The move is stock-specific: AZN rose +7.0% while the S&P 500 fell -1.8% and the Nasdaq 100 fell -3.5%, so the broad tape does not explain it. The catalyst was the Q3 2026 earnings release and call, where the company highlighted oncology and rare disease momentum, and headlines noted a beat plus a $1.5 billion savings plan; that combination is a company-event move, not a market move.
Move quality
This looks like a larger-than-normal but fundamentally supported move. Revenue is growing +7.3% YoY (TTM) and +6.7% YoY in the latest quarter, EPS is up +17.4% YoY (TTM), and margins are strong at gross +81.7%, operating +23.7%, and net +17.7%. Valuation is not cheap at PE 24.6 and PEG 2.36 — PEG is P/E divided by growth, so it describes what investors pay per point of growth when earnings growth is positive — which means the stock can react sharply to both good and bad news; here, though, the gain is anchored in real operating progress rather than a detached rerating. Beta is 1.28, so some amplified volatility is expected.
Next print
The next earnings date is not available this period, so I cannot anchor a forward calendar date here. The most recent report already set the near-term frame: revenue growth is +6.7% YoY in the latest quarter, EPS is +17.4% YoY (TTM), and margins remain elevated at gross +81.7%, operating +23.7%, and net +17.7%. The market will be watching whether oncology and rare disease momentum can offset cardiovascular headwinds, whether the $1.5 billion savings plan feeds through to margin support, and whether management can keep the AI-backed pipeline narrative credible after the Q3 beat.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track AZN with WhyIHold
Get a plain-English explanation the next time ASTRAZENECA PLC makes a big move — so you know whether it's benign or worth your attention.